Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2013 2
2014 3
2015 1
2016 7
2017 12
2018 11
2019 10
2020 11
2021 5
2022 7
2023 7
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Rebuttal From Drs Wells and Kokosi.
Wells AU, Kokosi MA. Wells AU, et al. Among authors: kokosi ma. Chest. 2017 Nov;152(5):922-923. doi: 10.1016/j.chest.2017.08.1176. Epub 2017 Sep 21. Chest. 2017. PMID: 28943277 No abstract available.
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, Hoyles RK, Parfrey H, Renzoni EA, Kokosi M, Wells AU, Ashby D, Szigeti M, Molyneaux PL; RECITAL Investigators. Maher TM, et al. Among authors: kokosi m. Lancet Respir Med. 2023 Jan;11(1):45-54. doi: 10.1016/S2213-2600(22)00359-9. Epub 2022 Nov 11. Lancet Respir Med. 2023. PMID: 36375479 Free article. Clinical Trial.
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO; TRAIL1 Network Investigators. Solomon JJ, et al. Lancet Respir Med. 2023 Jan;11(1):87-96. doi: 10.1016/S2213-2600(22)00260-0. Epub 2022 Sep 5. Lancet Respir Med. 2023. PMID: 36075242 Clinical Trial.
Progressive cystic lung disease with bullous destruction.
Anwar A, Kokosi M, Aldik G. Anwar A, et al. Among authors: kokosi m. Clin Med (Lond). 2022 Sep;22(5):478-481. doi: 10.7861/clinmed.2022-0287. Clin Med (Lond). 2022. PMID: 36507824 Free PMC article. No abstract available.
Pulmonary involvement in Sjögren syndrome.
Kokosi M, Riemer EC, Highland KB. Kokosi M, et al. Clin Chest Med. 2010 Sep;31(3):489-500. doi: 10.1016/j.ccm.2010.05.007. Clin Chest Med. 2010. PMID: 20692541 Review.
Combination of BAL and Computed Tomography Differentiates Progressive and Non-progressive Fibrotic Lung Diseases.
Barnett JL, Maher TM, Quint JK, Adamson A, Wu Z, Smith DJF, Rawal B, Nair A, Walsh SLF, Desai SR, George PM, Kokosi M, Jenkins G, Kouranos V, Renzoni EA, Rice A, Nicholson AG, Chua F, Wells AU, Molyneaux PL, Devaraj A. Barnett JL, et al. Among authors: kokosi m. Am J Respir Crit Care Med. 2023 Nov 1;208(9):975-982. doi: 10.1164/rccm.202305-0796OC. Am J Respir Crit Care Med. 2023. PMID: 37672028
73 results